ALK and non-small cell lung carcinoma: There are various classes of ALK-TKIs; however, second-generation ALK-TKIs, alectinib and brigatinib, have demonstrated significantly longer progression-free survival (PFS) than the first generation ALK-TKI crizotinib when used as a first-line treatment for ALK-positive NSCLC patients8–10.